profit from every $100 of sales.
$0$100
MindWalk
$0.99-1.00% today
-40.0% in 1 year
1-year low $0.991-year high $2.78
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What MindWalk sold, what it kept, and what it did with the cash.
Sales went from CA$19.4 million in 2022 to CA$24.5 million in 2025, with -CA$30.2 million of profit last year.
SalesProfit
MindWalk vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| MindWalk | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads MindWalk's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of CAD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 19 | 21 | 25 | 25 | |
| 11 | 12 | 12 | 14 | |
| -17 | -26 | -14 | -12 | |
| -12 | -21 | -23 | -29 | |
| -17 | -27 | -26 | -30 | |
| -0.85 | -1.07 | -1.02 | -0.91 | |
| 56.7% | 56.0% | 49.2% | 55.3% | |
| -86.1% | -123.9% | -56.1% | -49.7% | |
| -86.3% | -128.5% | -106.5% | -123.3% |
Balance sheet
| In millions of CAD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 94 | 78 | 60 | 44 |
| Cash | 30 | 8 | 3 | 11 |
| Total debt | 3 | 7 | 14 | 13 |
| Total liabilities | 18 | 20 | 24 | 21 |
| 75 | 58 | 36 | 24 | |
| 20 | 25 | 26 | 33 | |
| -16.0% | -33.7% | -45.9% | -72.5% | |
| -22.2% | -45.9% | -73.2% | -128.0% |
Cash flow
| In millions of CAD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -10 | -20 | -3 | -6 | |
| 1 | 1 | 1 | 1 | |
| -11 | -21 | -5 | -7 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 3 | 2 | 2 | 0 |
Valuation
- –
- –
- –
- 6.8×
- 2.7×
- –
- –
- -10.7%
- -45.0%
- 0.0%
Profitability
- 55.3%
- -49.7%
- -123.3%
- -58.3%
- -63.4%
- -42.5%
- -63.1%
- -52.5%
- -66.4%
- 24.9%
Growth
- +8.2%
- –
- −27.8%
- –
- +19.3%
Financial health
- –
- 0.24
- 15.3%
- -6,183.2×
- 3.74
- 3.64
- 0.79
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 4%of 946
Bottom 7%of 872
Bottom 39%of 868
Bottom 11%of 986
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Mar 12, 2026 | -0.06 | -0.04 | −50.0% |
| Dec 15, 2025 | -0.05 | -0.04 | −40.2% |
| Sep 15, 2025 | -0.07 | -0.04 | −75.0% |
| Jul 29, 2025 | -0.04 | -0.02 | −100.0% |
| Mar 28, 2025 | -0.06 | -0.06 | +0.0% |
| Dec 10, 2024 | -0.09 | -0.09 | +0.0% |
| Sep 16, 2024 | -0.11 | -0.09 | −22.2% |
| Jul 29, 2024 | -0.52 | -0.10 | −420.0% |
News
MindWalk GAAP EPS of -$0.13 misses by $0.08, revenue of $3.8M beats by $0.59MSeeking Alpha · Sep 14, 2026The newest story we have is from Sep 14, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
23No pass
Benjamin Graham
38No pass
Philip Fisher
25No pass
Peter Lynch
40No pass
Joel Greenblatt
0No pass
Charlie Munger
26No pass
Terry Smith
26No pass
Questions about MindWalk
Is MindWalk a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the MindWalk AI analysis
What does MindWalk do?
MindWalk Holdings Corp. operates as a bio-native AI company. It focuses on the integration of artificial intelligence, multi-omics data, and advanced laboratory research to accelerate the discovery and development of biologics. It is in Biotechnology.
Does MindWalk pay a dividend?
No. MindWalk does not pay a dividend at the moment.
Is MindWalk stock halal?
Yes. MindWalk passes our halal screen: its business is permitted and its debt is 20% of its market value, under the 30% limit. How we check
How has MindWalk stock done over the past year?
Down 40.0% over the past twelve months, to $0.99. It traded between $0.99 and $2.78 and is 64.4% below its high.
Who are MindWalk's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with MindWalk's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.